ABSTRACT
The first human genome sequence a decade ago and the subsequent ‘big” international consortia and projects including HapMap 1, 2 and more recently 3 have created a large reference database with millions of genetic variants. This genome sequencing-based achievement allows high-tech biotechnology companies to provide microchips with large sets of genetic variants. Based on these single-nucleotide-polymorphisms (SNPs) arrays, genome-wide association studies (GWAS) have already identified multiple genetic variants for the first time. In addition, next-generation sequencing (NGS) provides the ability of whole genome sequencing faster and cheaper than earlier. National, particularly in the USA , and international whole and partial (exome) genome sequencing projects are underway and as new are being launching the list of genomes sequencing in health and patients is rapidly growing. At the end of 2011, a nature survey estimates that `30,000 human whole genomes sequence will be completed. Under the light of this biomedical revolution, and advances in systems biology approaches, will Surgical Oncology be changed?
(Citation: Gastric & Breast Cancer 2010; 9(4): 144-149)
|
